<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960645</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-380-5310</org_study_id>
    <nct_id>NCT03960645</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters</brief_title>
  <official_title>A Phase 1b, Open-label Study to Evaluate the PK, Safety and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the steady state pharmacokinetics of
      bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF)
      50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed
      pregnant women in their second and third trimesters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau of BIC</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of emtricitabine (FTC) and tenofovir alafenamide (TAF)</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug during the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of BIC and FTC</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clast of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Clast is defined as the last observable concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: t1/2 of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CL/F of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Vz/F of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: λz of BIC, FTC, and TAF</measure>
    <time_frame>Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 50 Copies/mL Using the Missing = Excluded Approach</measure>
    <time_frame>At the Time of Delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B/F/TAF for up to approximately 38 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>50/200/25 mg FDC tablet administered orally once daily without regard to food</description>
    <arm_group_label>B/F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  The ability to understand and sign a written informed consent form, which must be
             obtained prior to initiation of study procedures

          -  With singleton pregnancy, at least 12 weeks but not more than 31 weeks pregnant at the
             time of screening

          -  Agree not to breastfeed for the duration of the study

          -  Currently on a stable antiretroviral regimen for ≥ 6 months preceding the screening
             visit

          -  Documented plasma HIV-1 RNA levels of &lt; 50 copies/mL for ≥ 6 months preceding the
             screening visit and have HIV-1 RNA &lt; 50 copies/mL at the screening visit

          -  Have no documented or suspected resistance to FTC, Tenofovir (TFV), or integrase
             strand-transfer inhibitors (INSTIs) including, but not limited to, the reverse
             transcriptase resistance mutations K65R or M184V/I

               -  Historic genotype reports will be collected if available

          -  Have a normal ultrasound, completed locally prior to the Day 1 visit, with no evidence
             of any fetal malformation or structural abnormality affecting either fetus or placenta

          -  Normal maternal alfa-fetoprotein level at the screening visit

        Key Exclusion Criteria:

          -  Have chronic hepatitis B virus (HBV)

          -  Have active hepatitis C virus (HCV) infection

          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior
             to screening

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miller Children's &amp; Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Dominicano de Estudios Virologics (IDEV)</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10103</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salvador B Gautier Hospital</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10514</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maternal Infant Studies Center (CEMI)</name>
      <address>
        <city>San Juan</city>
        <zip>00925</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine-Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Muang</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute for Health Sciences, Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Pathumwan</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Puerto Rico</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

